4.85

1.22% -0.06

Ventyx Biosciences Inc (VTYX)

Overview News Price History Option Chain Financials Why VTYX Down? Discussions Forecast

Ventyx Biosciences Inc stock is currently priced at $4.85, with a 24-hour trading volume of 851.04K. It has seen a -1.22% decreased in the last 24 hours and a -6.37% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $4.88 pivot point. If it approaches the $4.59 support level, significant changes may occur.

Previous Close:

$4.91

Open:

$5.05

24h Volume:

851.04K

Market Cap:

$341.92M

Revenue:

Net Income/Loss:

$-192.96M

P/E Ratio:

-1.7321

EPS:

-2.8

Net Cash Flow:

$-167.04M

1W Performance:

+23.41%

1M Performance:

-6.37%

6M Performance:

-68.87%

1Y Performance:

-87.58%

1D Range:

$4.85

$5.24

52W Range:

$1.865

$40.58

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name

Ventyx Biosciences Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

760-593-4832

Address

662 Encinitas Boulevard, Suite 250, Encinitas

Employee

Twitter

Next Earnings Date

2024-03-25

Latest SEC Filings

VTYX's Discussions on Twitter

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-14-23	Resumed	Credit Suisse	Outperform
Mar-21-23	Initiated	Wells Fargo	Overweight
Dec-19-22	Initiated	Goldman	Buy
Nov-17-22	Initiated	Morgan Stanley	Overweight
Sep-07-22	Initiated	Stifel	Buy
Sep-01-22	Initiated	H.C. Wainwright	Buy
May-09-22	Initiated	Credit Suisse	Outperform
Mar-31-22	Initiated	Canaccord Genuity	Buy
Feb-01-22	Initiated	Oppenheimer	Outperform
Nov-15-21	Initiated	Jefferies	Buy
Nov-15-21	Initiated	Piper Sandler	Overweight

View All

Ventyx Biosciences Inc Stock (VTYX) Latest News

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire Inc.

What Makes Ventyx Biosciences (VTYX) a New Buy Stock

Zacks Investment Research

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session

Benzinga

Dow Turns Higher; GDS Holdings Shares Climb

Benzinga

Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Crude Oil Edges Higher; Lexicon Pharmaceuticals Shares Jump

Benzinga

Ventyx Biosciences Inc Stock (VTYX) Financials Data

Ventyx Biosciences Inc (VTYX) Net Income 2024

VTYX net income (TTM) was -$192.96 million for the quarter ending December 31, 2023, a -77.97% decrease year-over-year.

Ventyx Biosciences Inc (VTYX) Cash Flow 2024

VTYX recorded a free cash flow (TTM) of -$167.04 million for the quarter ending December 31, 2023, a -68.64% decrease year-over-year.

Ventyx Biosciences Inc (VTYX) Earnings per Share 2024

VTYX earnings per share (TTM) was -$3.30 for the quarter ending December 31, 2023, a -60.98% decline year-over-year.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.